In 2024, Blackstone, the world’s largest alternative assets manager, launched a $750 million investment in Moderna to support the development of its mRNA flu vaccine. In February, the FDA rejected a review of the vaccine’s Phase 3 clinical trial. By early March, the head of the agency’s vaccine division was gone from the FDA, and the review was back on.
